Treatment of mice with four consecutive doses of anti-mouse VEGF-A mAbs resulted in significant long-term reduction of disease severity (as revealed by peripheral arthritis score) compared to untreated animals as well as mice treated with the same doses of nonspecific mAbs of the same isotype (Figure 1B). Here, VEGFA is linked to arthritic joint disease.